Advertisement
New Zealand markets closed
  • NZX 50

    11,946.43
    +143.15 (+1.21%)
     
  • NZD/USD

    0.5956
    +0.0019 (+0.33%)
     
  • NZD/EUR

    0.5556
    +0.0010 (+0.18%)
     
  • ALL ORDS

    7,937.50
    -0.40 (-0.01%)
     
  • ASX 200

    7,683.00
    -0.50 (-0.01%)
     
  • OIL

    83.07
    +0.26 (+0.31%)
     
  • GOLD

    2,335.60
    -2.80 (-0.12%)
     
  • NASDAQ

    17,526.80
    +55.33 (+0.32%)
     
  • FTSE

    8,040.38
    0.00 (0.00%)
     
  • Dow Jones

    38,460.92
    -42.77 (-0.11%)
     
  • DAX

    18,088.70
    -48.95 (-0.27%)
     
  • Hang Seng

    17,276.85
    +75.58 (+0.44%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • NZD/JPY

    92.6680
    +0.5530 (+0.60%)
     

Novo Nordisk Focuses on Expanding Semaglutide’s Label

Novo Nordisk Focuses on Expanding Semaglutide’s Label

Based on readouts from this study, the company plans to evaluate the efficacy and safety of once-a-week semaglutide therapy in NASH indications in its Phase 3 trial. According to a Diabetes Care report, ~80% of NASH patients suffer from obesity.